Christopher U. Jones

17.0k total citations · 6 hit papers
68 papers, 10.3k citations indexed

About

Christopher U. Jones is a scholar working on Pulmonary and Respiratory Medicine, Otorhinolaryngology and Surgery. According to data from OpenAlex, Christopher U. Jones has authored 68 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pulmonary and Respiratory Medicine, 40 papers in Otorhinolaryngology and 18 papers in Surgery. Recurrent topics in Christopher U. Jones's work include Head and Neck Cancer Studies (40 papers), Prostate Cancer Treatment and Research (15 papers) and Advanced Radiotherapy Techniques (14 papers). Christopher U. Jones is often cited by papers focused on Head and Neck Cancer Studies (40 papers), Prostate Cancer Treatment and Research (15 papers) and Advanced Radiotherapy Techniques (14 papers). Christopher U. Jones collaborates with scholars based in United States, Canada and Australia. Christopher U. Jones's co-authors include Paul M. Harari, David Raben, James A. Bonner, J. Giralt, José Baselga, Hagop Youssoufian, Eric K. Rowinsky, Roger B. Cohen, Ranjan Sur and Adam S. Garden and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Christopher U. Jones

67 papers receiving 10.1k citations

Hit Papers

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma o... 2000 2026 2008 2017 2006 2009 2000 2009 2011 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
    2006 3.7k citations James A. Bonner, Paul M. Harari et al. profile →
  2. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
    2009 1.4k citations James A. Bonner, Paul M. Harari et al. profile →
  3. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
    2000 983 citations Karen K. Fu, Thomas F. Pajak et al. International Journal of Radiation Oncology*Biology*Physics profile →
  4. Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225
    2009 531 citations Jonathan Harris, Adam S. Garden et al. Journal of Clinical Oncology profile →
  5. Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
    2011 473 citations Christopher U. Jones, D.G. McGowan et al. profile →
  6. Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413
    2003 471 citations Mitchell Machtay, Christopher U. Jones et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher U. Jones United States 28 5.2k 5.0k 3.7k 3.3k 1.5k 68 10.3k
Sharon A. Spencer United States 38 4.3k 0.8× 3.7k 0.7× 2.7k 0.7× 3.9k 1.2× 992 0.6× 146 8.4k
K. Kian Ang United States 43 3.1k 0.6× 4.9k 1.0× 3.1k 0.8× 3.3k 1.0× 2.0k 1.3× 75 9.0k
Jacques Bernier Switzerland 39 6.7k 1.3× 6.4k 1.3× 3.6k 1.0× 4.9k 1.5× 1.2k 0.8× 112 13.4k
Roy B. Tishler United States 44 2.1k 0.4× 3.3k 0.7× 2.6k 0.7× 2.6k 0.8× 892 0.6× 178 6.4k
P. Maingon France 47 4.7k 0.9× 3.6k 0.7× 6.8k 1.8× 6.7k 2.0× 540 0.4× 267 13.3k
Mahmut Özsahin Switzerland 43 2.1k 0.4× 2.8k 0.6× 2.3k 0.6× 2.7k 0.8× 821 0.5× 149 6.9k
Eric J. Sherman United States 47 2.4k 0.5× 2.9k 0.6× 3.3k 0.9× 2.7k 0.8× 1.4k 0.9× 269 8.6k
Joseph K. Salama United States 45 3.7k 0.7× 1.4k 0.3× 2.8k 0.8× 2.5k 0.8× 594 0.4× 217 7.2k
Muhyi Al‐Sarraf United States 47 6.0k 1.2× 5.0k 1.0× 4.4k 1.2× 7.1k 2.1× 1.1k 0.7× 146 12.2k
Marvin Rotman United States 27 4.4k 0.9× 2.2k 0.4× 2.8k 0.7× 2.3k 0.7× 643 0.4× 67 7.6k

Countries citing papers authored by Christopher U. Jones

Since Specialization
Citations

This map shows the geographic impact of Christopher U. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher U. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher U. Jones more than expected).

Fields of papers citing papers by Christopher U. Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher U. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher U. Jones. The network helps show where Christopher U. Jones may publish in the future.

Co-authorship network of co-authors of Christopher U. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher U. Jones. A scholar is included among the top collaborators of Christopher U. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher U. Jones. Christopher U. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galloway, Thomas J., Stephanie L. Pugh, John A. Ridge, et al.. (2025). Long-Term Feeding Tube Use in Head and Neck Cancer Survivors—An Analysis of Patient- and Treatment-Related Factors. International Journal of Radiation Oncology*Biology*Physics. 123(3). 703–712.
2.
Garden, Adam S., Jonathan Harris, Avraham Eisbruch, et al.. (2023). Final Report of NRG Oncology RTOG 0022: A Phase 1/2 Study of Conformal and Intensity Modulated Radiation for Oropharyngeal Cancer. International Journal of Radiation Oncology*Biology*Physics. 117(2). 333–340. 5 indexed citations
3.
4.
Mell, Loren K., Hanjie Shen, Phuc Félix Nguyen‐Tan, et al.. (2019). Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research. 25(23). 7078–7088. 18 indexed citations
5.
Hamstra, Daniel A., Stephanie L. Pugh, Herbert Lepor, et al.. (2019). Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiotherapy and Oncology. 141. 137–143. 6 indexed citations
6.
Ali, Arif N., Peixin Zhang, W.K. Alfred Yung, et al.. (2018). NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. Journal of Neuro-Oncology. 137(1). 39–47. 25 indexed citations
7.
Xiao, Canhua, Qiang Zhang, Phuc Félix Nguyen‐Tan, et al.. (2016). Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. International Journal of Radiation Oncology*Biology*Physics. 97(4). 667–677. 29 indexed citations
8.
Schwartz, David A., Jonathan Harris, Min Yao, et al.. (2015). Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522. International Journal of Radiation Oncology*Biology*Physics. 91(4). 721–729. 57 indexed citations
9.
Krauss, Daniel, Chen Hu, Jean-Paul Bahary, et al.. (2015). Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408. International Journal of Radiation Oncology*Biology*Physics. 92(4). 863–873. 22 indexed citations
10.
Kish, Julie A., Qiang Zhang, Corey J. Langer, et al.. (2015). The effect of age on outcome in prospective, phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- chemotherapy in locally advanced (LA) head and neck cancer (HNC).. Journal of Clinical Oncology. 33(15_suppl). 6003–6003. 9 indexed citations
11.
Trotti, Andy, Qiang Zhang, Søren M. Bentzen, et al.. (2014). Randomized Trial of Hyperfractionation Versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord (RTOG 9512). International Journal of Radiation Oncology*Biology*Physics. 89(5). 958–963. 50 indexed citations
12.
Beitler, Jonathan J., Qiang Zhang, Karen K. Fu, et al.. (2014). Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 89(1). 13–20. 148 indexed citations
13.
Chambers, Mark S., Marshall R. Posner, Christopher U. Jones, et al.. (2007). Cevimeline for the Treatment of Postirradiation Xerostomia in Patients With Head and Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 68(4). 1102–1109. 67 indexed citations
14.
Lustig, Robert A., Wendy Seiferheld, Brian Berkey, et al.. (2007). Imaging Response in Malignant Glioma, RTOG 90-06. American Journal of Clinical Oncology. 30(1). 32–37. 15 indexed citations
15.
Harris, Jonathan, Adam S. Garden, W. Straube, et al.. (2007). Phase II Multi-Institutional Study of IMRT ± Chemotherapy for Nasopharyngeal Carcinoma (RTOG 0225): Preliminary Results. International Journal of Radiation Oncology*Biology*Physics. 69(3). S13–S14. 8 indexed citations
16.
Chambers, Mark S., Christopher U. Jones, Merrill A. Biel, et al.. (2007). Open-Label, Long-Term Safety Study of Cevimeline in the Treatment of Postirradiation Xerostomia. International Journal of Radiation Oncology*Biology*Physics. 69(5). 1369–1376. 31 indexed citations
17.
Hagan, Michael P., Kathryn Winter, Donald S. Kaufman, et al.. (2003). RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. International Journal of Radiation Oncology*Biology*Physics. 57(3). 665–672. 152 indexed citations
18.
Owen, Jean B., Perry W. Grigsby, André Konski, et al.. (2001). Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04. International Journal of Radiation Oncology*Biology*Physics. 49(3). 633–639. 11 indexed citations
19.
Fu, Karen K., Thomas F. Pajak, Andy Trotti, et al.. (2000). A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. International Journal of Radiation Oncology*Biology*Physics. 48(1). 7–16. 983 indexed citations breakdown →
20.
Scott, Charles, Charles W. Scarantino, Raul C. Urtasun, et al.. (1998). Validation and Predictive Power of Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis Classes for Malignant Glioma Patients: A Report Using RTOG 90-06☆. International Journal of Radiation Oncology*Biology*Physics. 40(1). 51–55. 266 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sharon A. Spencer Breakdown of academic impact, for papers by K. Kian Ang Breakdown of academic impact, for papers by Jacques Bernier Breakdown of academic impact, for papers by Roy B. Tishler Breakdown of academic impact, for papers by P. Maingon Breakdown of academic impact, for papers by Mahmut Özsahin Breakdown of academic impact, for papers by Eric J. Sherman Breakdown of academic impact, for papers by Joseph K. Salama Breakdown of academic impact, for papers by Muhyi Al‐Sarraf Breakdown of academic impact, for papers by Marvin Rotman
Rankless by CCL
2026